|
| Time/Date | Code | Headline | Source | Impact |
|---|---|---|---|---|
| 15:47 14-May-2013 | TRX | Annual Report and Notice of AGM | RNS | -6.96% |
| 07:00 13-May-2013 | TRX | Preliminary results for the year ended 31 Jan 2013 | RNS | -6.67% |
| 07:00 03-May-2013 | TRX | Notice of Results | RNS | -0.34% |
| 07:00 02-May-2013 | TRX | Results of dCELL Dermis trial | RNS | +0.69% |
| 07:00 29-Apr-2013 | TRX | Change of Nominated Adviser and Broker | RNS | +0.69% |
| 07:00 16-Apr-2013 | TRX | Approval for start of clinical research trial | RNS | -5.97% |
| 07:00 02-Apr-2013 | TRX | Tissue Regenix makes appointment to US subsidiary | RNS | -3.06% |
| 07:00 11-Mar-2013 | TRX | Director Change | RNS | -0.57% |
| 14:38 15-Feb-2013 | TRX | Holding(s) in Company | RNS | +1.13% |
| 07:00 14-Feb-2013 | TRX | Successful safety study of dCELL® Meniscus | RNS | +1.52% |
| 14:57 11-Feb-2013 | TRX | Directorate Change | RNS | +0.76% |
| 07:15 09-Jan-2013 | TRX | Holding(s) in Company | RNS | -3.28% |
| 11:21 30-Nov-2012 | TRX | Tissue Regenix board changes | RNS | -2.27% |
| 07:00 26-Nov-2012 | TRX | Sets up US subsidiary | RNS | -1.57% |
| 07:00 19-Nov-2012 | TRX | Adds new patent global licence portfolio | RNS | -0.67% |
| 07:00 04-Oct-2012 | TRX | Interim data from clinical trial of dCELL® Dermis | RNS | +7.22% |
| 07:00 04-Oct-2012 | TRX | Half Yearly Report | RNS | +7.22% |
| 10:57 01-Oct-2012 | TRX | Tissue Regenix - senior development appointment | RNS | +17.49% |
| 15:30 28-Sep-2012 | TRX | Notice of Results | RNS | +19.34% |
| 07:00 07-Sep-2012 | TRX | dCELL(R) vascular patch is safe and effective | RNS | 0.00% |
The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.
By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.
You will be redirected in five seconds.
You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.
The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.
By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.
You will be redirected in five seconds